Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-b

[PeteS in CA]

Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/vaxzevria-and-mrna-covid-19-vaccines-showed-similar-and-favourable-safety-profiles-in-a-population-based-cohort-study-of-over-a-million-people.html

In a large real-world study, data published as a pre-print on The Lancet server from over one million individuals assessed the incidence rates of blood clotting disorders of thromboembolism and thrombocytopenia, including the very rare thrombosis with thrombocytopenia (TTS) following vaccination with an mRNA vaccine or Vaxzevria, and compared them with expected rates in a general population and in people with COVID-19.

Safety profiles of Vaxzevria, and the mRNA-based vaccine were similar and overall favourable. Very rare clotting disorders (TTS) were observed with both vaccines but these were in line with what would be expected in the general population and lower than in those diagnosed with COVID-19.1 Follow-up time was not sufficient to report rates after two doses of Vaxzevria, though other studies have shown rates of rare blood clotting events to be lower after a second dose.2

Regardless of the vaccine used, the increase in rates of thrombosis among persons infected with COVID-19 was far higher than among those vaccinated. Rates of venous thromboembolism were eight times higher after a diagnosis of COVID-19 infection compared with the expected rate.
...
The analysis included 945,941 mRNA participants (778,534 with two doses), 426,272 Vaxzevria participants, conducted between 27 December 2020 and 19 May 2021. It also included 222,710 COVID-19 participants identified between 1 September 2020 and 1 March 2021, and 4,570,149 background participants as of 1 January 2017 from a public health database held in Catalonia, Spain.

Vaxzevria is AstraZeneca's vaccine, which is not authorized for use in the US, but is in much of the rest of the world.

I haven't seen any news about Tonguetwistria vaccine safety and effectiveness.

[jmyrlefuller]

Most of what I've seen about the AZ vaccine's efficacy is that it ranks quite low. It's about as effective with two shots as J&J is with one shot. (Which partially explains the surge in the UK.) In fact, a number of countries that started off with AZ as the first dose (such as Canada, which delayed the second dose a ridiculously long time) are now giving an mRNA shot as the second dose instead of the second AZ shot. The WHO doesn't like that.

With as many vaccines as have been administered here in the USA, there really isn't a reason to introduce the AZ shot. It adds nothing to our arsenal except more doses.

[thackney]

The Delta for Covid-19 vaccine efficacy
https://www.evaluate.com/vantage/articles/news/trial-results/delta-covid-19-vaccine-efficacy
July 21, 2021

...With Delta quickly becoming the dominant Covid-19 variant in the west the results will be seen as a major endorsement of the current generation of vaccines from Pfizer/Biontech and Astrazeneca. The headline numbers, revealing 67-88% efficacy after a double dose, was previously revealed by Public Health England, but the NEJM paper has laid out the data and their importance in full....